Appointment dossier — Breast Invasive Ductal Carcinoma (IDC)
Bring this to your appointment. It summarizes what published studies report — it is not medical advice and does not say anything works. Decisions are yours and your care team’s.
Compounds studied in Breast Invasive Ductal Carcinoma (IDC)
No studies or cited compounds on file for this cancer yet.
Open recruiting trials (18)
- NCT06081959 · Phase 3 — Study of SKB264 for Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast Cancer (China)
- NCT06993714 · Phase 2 — 3D-printed Biodegradable Breast Implants for Breast Restoration (China)
- NCT06500208 · Phase 2 — Neoadjuvant Adebrelimab and Chemotherapy in High-rish ER+/HER2- BC (China)
- NCT05305924 · Phase 2 — Fulvestrant+Abemaciclib With Run-In of Fulvestrant in Er-Positive, Her2-Negative Metastatic Breast Cancer (United States)
- NCT07284836 · Phase 2 — Phase II Trial of Albumin-Bound Paclitaxel Combined With Nedaplatin (TP) Via Hepatic Arterial Infusion for Advanced Breast Cancer Patients With Liver Metastases After Failure of Standard Therapy (China)
- NCT06532812 · Phase 1 / Phase 2 — TIL Gean Therapy Combined With Immunotherapy for Advanced or Metastatic Refractory Breast Cancer (China)
- NCT06618287 · Phase 1 / Phase 2 — A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors (United States)
- NCT05005403 · Phase 1 — Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan (United States)
- NCT02897700 · Phase 1 — A Randomized Trial of Chemotherapy in Surgical Patients With Infiltrating Ductal Carcinoma of Breast (China)
- NCT06253871 · Phase 1 — A Phase 1/1b Study of IAM1363 in HER2 Cancers (United States)
- NCT04842812 · Phase 1 — Engineered TILs/CAR-TILs to Treat Advanced Solid Tumors (China)
- NCT07297667 · Phase 1 — GCAR1, a Chimeric Antigen Receptor (CAR) T-CELL Therapy for Relapsed/Refractory GPNMB-Expressing Solid Tumours (Canada)
- NCT05504707 · Phase 1 — DecipHER Trial - DC1 Tx for Early-Stage TNBC and ER Low Positive Breast Cancer (United States)
- NCT03321045 · Early Phase 1 — Positron Emission Tomography (PET) Imaging With Zirconium-89 (89Zr)-Trastuzumab for Prediction of HER2 Targeted Therapy Effectiveness (United States)
- NCT06058650 — Molecular Breast Imaging Guidance for Breast Biopsy for Patients With Breast Abnormalities (United States)
- NCT05502224 — Multidisciplinary Approach to Fatigue (Belgium)
- NCT06259162 — LAG3 Expression in Triple Negative Breast Cancer (South Korea)
- NCT04291378 — The DBCG Proton Trial: Photon Versus Proton Radiation Therapy for Early Breast Cancer (Denmark)
Most-relevant first: trials that name Breast Invasive Ductal Carcinoma (IDC), then broader trials you may still qualify for. Eligibility is decided by each trial's team — bring these NCT numbers to your appointment.
Questions to ask your oncologist
- Has my tumor been tested for ER (estrogen receptor), and would the result open up targeted treatments or trials?
- Has my tumor been tested for PR (progesterone receptor), and would the result open up targeted treatments or trials?
- Has my tumor been tested for HER2 (ERBB2) amplification/overexpression, and would the result open up targeted treatments or trials?
- Of the open trials I found (for example NCT06081959), am I eligible for any — here or at a larger cancer center?
- Which subtype do I have (luminal A/B, HER2+, TNBC) and what is our best curative plan?
- Do I need neoadjuvant therapy to increase breast conservation and tailor adjuvant options by response (pCR vs residual)?
- Will a genomic assay (e.g., Oncotype DX) change whether I need chemotherapy?
- Am I a candidate for lumpectomy with oncoplastic techniques, or is mastectomy preferable?
- Do I qualify for Z0011-type omission of axillary dissection or targeted axillary dissection after neoadjuvant therapy?
- What radiation fields (breast/chest wall, nodes) and schedule (hypofractionation, 5-fraction, boost) fit my case?
- How does reconstruction timing interact with radiation to optimize outcomes?
- Am I eligible for CDK4/6, PI3K/AKT/mTOR, PARP inhibitors, or ADCs (T-DXd, sacituzumab)?
- Should we test for ESR1/PIK3CA/AKT1/PTEN through ctDNA now or at progression to direct targeted therapy?
- What is our cardiac monitoring plan on HER2 therapy or anthracyclines?
- How will we detect and manage ILD risk on T-DXd and stomatitis on everolimus?
- What’s the plan for diarrhea on abemaciclib/capecitabine and hyperglycemia/rash on alpelisib/capivasertib?
- Should I pursue fertility preservation before chemo, and how would ovarian suppression fit in?
- Can I pause endocrine therapy in the future for pregnancy under supervision?
- How will we prevent lymphedema and bone loss, and what are my DEXA and bone-agent plans?
- Which clinical trials fit my biomarkers (ESR1, PIK3CA, BRCA/PALB2, HER2-low)?
- What is our imaging and clinic follow-up cadence during and after treatment?
- What support do you offer for fatigue, cognitive changes, sexual health, and return to work?